Clinical Trial

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Study acronym: i-LIVER
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the liver of people with chronic hepatitis B. The main questions it aims to answer are: * how well is it working in the liver * how does Imdusiran affect the hepatitis B virus Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran, and the second 8 weeks after the last dose of Imdusiran.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2023-11-30; most recent amendment 2025-09-08.
Status change: Not Yet Recruiting → Recruiting 2024-07-25
Trial Details
NCT Number NCT06154278
Lead Sponsor University of Maryland, Baltimore
Collaborators: Arbutus Biopharma Corporation
Conditions Chronic Hepatitis B
Enrollment 10 participants
Start Date 2024-07-25
Primary Completion 2026-12-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-11